23andMe Holding Co (ME) - שיעור רווח גולמי

A unique array of genetic data forms a powerful defensive barrier for 23andMe Holding Co. (ME). The company generates revenue through the sale of DNA tests and partnerships with pharmaceutical behemoths. The gross margin as a percentage of revenue clearly demonstrates profitability, where 40.60 determines the current value of this metric. The integration of consumer data into scientific research transforms the business into a central hub for modern personalized medicine.
פילוחי מדדים פיננסיים ומדדי שוק עבור 23andMe (ME)

To minimize long-term risks, it is crucial for investors to monitor production efficiency and the cost of capital. In the case of 23andMe Holding Co. (ME), operating profitability depends on the synergy between genetic databases and partnerships with pharma behemoths in the development of targeted drugs. By analyzing the gross margin percentage, you can see the portion of revenue minus direct costs, which determines the business's resilience to external shocks and the level of WACC.